do the numbers stack up? check it out..., page-10

It would have helped if you'd clearly listed these assumptions in your first mail. Unfortunately the valuation you've given lacks the necessary context/is impossible to evaluate - you're saying that you're basing it on the Gene well alone, but then you compare to the current price which has existing assets embedded into it.

I'm from a statistics background - you compare apples and oranges by taking Gene in isolation to compare against a SP value that embeds other parameters. It is impossible to critique your flawed base argument. Sorry.

The only thing that could possibly be compared by looking at Gene alone is an analysis against other company share price changes in response to a single bopd increase similar in size to that of SSN (and even that would be dodgy in the extreme, statistically speaking)